Alan Rubino

Alan Rubino

(Board Member )

Alan L. Rubino just recently assumed the role of President and Chief Executive Officer of RenovaCare, Inc. who is focused on cell therapies and effective device delivery. Prior to RenovaCare, Mr. Rubino led an effective turnaround of Emisphere Technologies, Inc. as the company’s President and Chief Executive Officer for over seven years from September 2012 to October 2019 which culminated in the approval and launch of its partner, Novo Nordisk’s Rybelsus therapeutic which was approved by the FDA as the world’s first oral GLP-1 therapeutic for diabetes. Mr. Rubino continues to enjoy a highly successful and rewarding career that spans over 35 years at every level of the biopharmaceutical and device therapeutics industry.

Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products and achieved major success through the acquisition, marketing, and eventual sale of its herpes labialis drug, Denavir® where the team tripled sales in 18 months and sold then sold the asset to Renaissance Pharmaceuticals, for a multiple of three times sales. Mr. Rubino served before New American Therapeutics, Inc. as the CEO and President of Akrimax Pharmaceuticals, where he and team acquired Tirosint® and NitroMist®, two key NDA approved launch products. Rounding out his background, he had also been President and COO of another publicly-held entity, Pharmos Corporation, where he led the transformation of the company through the acquisition of Vela Pharmaceuticals. Mr. Rubino also spent four years in senior leadership positions on the strategic services side of the healthcare sector with two other public companies, Cardinal Health and PDI Inc.

A major portion of Mr. Rubino’s highly successful career includes his twenty-four years spent at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies. At Roche, he was the youngest corporate officer ever designated and an 11 year member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning. Among his many accomplishment was launching the world’s first biologic product, Roferon-A (interferon-alfa 2a) in 1986.

Mr. Rubino currently serves on the Corporate Boards of Vericel Inc., Genisphere, Inc. and Sanuwave Health, Inc. He has served for the past 20 years on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino holds a B.A. in economics from Rutgers University along with a full minor in biology and chemistry. He also attended multiple executive education courses at Harvard Business School and the University of Lausanne in Switzerland.